inflammation

reshuffle pipeline target reorganize shift change
Biotech

Celldex drops phase 1 tumor bispecific to focus on inflammation

Celldex Therapeutics has halted work on its solid-tumor-focused bispecific as the biotech prioritizes its work in inflammation.
James Waldron Nov 7, 2024 7:25am
pay deal hand over cash licensing transaction money

Ocean Biomedical pens $32M pact for Polish YKL-40 inhibitors

Oct 15, 2024 10:05am
GSK

GSK blockbuster hope depemokimab shrinks polyps in ph. 3 trials

Oct 14, 2024 4:51am
A patient receives hemodialysis

Invizius completes first-in-human ‘angry blood’ dialysis study

Jun 13, 2024 12:06pm
craft scissors glue paper glue stick

Takeda gets crafty with molecular glue deal worth $1.2B biobucks

May 23, 2024 5:30am
Johnson Johnson JJ

J&J hooks Proteologix for at least $850M in cash

May 16, 2024 10:12am